| 000 | 01802 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515025459.0 | ||
| 264 | 0 | _c20060718 | |
| 008 | 200607s 0 0 eng d | ||
| 022 | _a1084-9785 | ||
| 024 | 7 |
_a10.1089/cbr.2006.21.88 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWong, Jeffrey Y C | |
| 245 | 0 | 0 |
_aA phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. _h[electronic resource] |
| 260 |
_bCancer biotherapy & radiopharmaceuticals _cApr 2006 |
||
| 300 |
_a88-100 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoembryonic Antigen _xbiosynthesis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 1-Ring _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _ximmunology |
| 650 | 0 | 4 |
_aImmunotoxins _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 |
_aNeoplasms _ximmunology |
| 650 | 0 | 4 |
_aRadioimmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aYttrium Radioisotopes _xadverse effects |
| 700 | 1 | _aChu, David Z | |
| 700 | 1 | _aWilliams, Lawrence E | |
| 700 | 1 | _aLiu, An | |
| 700 | 1 | _aZhan, Jiping | |
| 700 | 1 | _aYamauchi, Dave M | |
| 700 | 1 | _aWilczynski, Sharon | |
| 700 | 1 | _aWu, Anna M | |
| 700 | 1 | _aYazaki, Paul J | |
| 700 | 1 | _aShively, John E | |
| 700 | 1 | _aLeong, Lucille | |
| 700 | 1 | _aRaubitschek, Andrew A | |
| 773 | 0 |
_tCancer biotherapy & radiopharmaceuticals _gvol. 21 _gno. 2 _gp. 88-100 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/cbr.2006.21.88 _zAvailable from publisher's website |
| 999 |
_c16306041 _d16306041 |
||